Cargando…
The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis
Long QT syndrome (LQTS) is an arrhythmic heart disease caused by congenital genetic mutations, and results in increased occurrence rates of polymorphic ventricular tachyarrhythmias and sudden cardiac death (SCD). Clinical evidence from numerous previous studies suggested that beta blockers (BBs), in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768040/ https://www.ncbi.nlm.nih.gov/pubmed/33381033 http://dx.doi.org/10.3389/fphar.2020.579525 |
_version_ | 1783629095192494080 |
---|---|
author | Han, Lu Liu, Fuxiang Li, Qing Qing, Tao Zhai, Zhenyu Xia, Zirong Li, Juxiang |
author_facet | Han, Lu Liu, Fuxiang Li, Qing Qing, Tao Zhai, Zhenyu Xia, Zirong Li, Juxiang |
author_sort | Han, Lu |
collection | PubMed |
description | Long QT syndrome (LQTS) is an arrhythmic heart disease caused by congenital genetic mutations, and results in increased occurrence rates of polymorphic ventricular tachyarrhythmias and sudden cardiac death (SCD). Clinical evidence from numerous previous studies suggested that beta blockers (BBs), including atenolol, propranolol, metoprolol, and nadolol, exhibit different efficacies for reducing the risk of cardiac events (CEs), such as syncope, arrest cardiac arrest (ACA), and SCD, in patients with LQTS. In this study, we identified relevant studies in MEDLINE, PubMed, embase, and Cochrane databases and performed a meta-analysis to assess the relationship between the rate of CEs and LQTS individuals with confounding variables, including different gender, age, and QTc intervals. Moreover, a network meta-analysis was not only established to evaluate the effectiveness of different BBs, but also to provide the ranked efficacies of BBs treatment for preventing the recurrence of CEs in LQT1 and LQT2 patients. In conclusion, nadolol was recommended as a relatively effective strategy for LQT2 in order to improve the prognosis of patients during a long follow-up period. |
format | Online Article Text |
id | pubmed-7768040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77680402020-12-29 The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis Han, Lu Liu, Fuxiang Li, Qing Qing, Tao Zhai, Zhenyu Xia, Zirong Li, Juxiang Front Pharmacol Review Long QT syndrome (LQTS) is an arrhythmic heart disease caused by congenital genetic mutations, and results in increased occurrence rates of polymorphic ventricular tachyarrhythmias and sudden cardiac death (SCD). Clinical evidence from numerous previous studies suggested that beta blockers (BBs), including atenolol, propranolol, metoprolol, and nadolol, exhibit different efficacies for reducing the risk of cardiac events (CEs), such as syncope, arrest cardiac arrest (ACA), and SCD, in patients with LQTS. In this study, we identified relevant studies in MEDLINE, PubMed, embase, and Cochrane databases and performed a meta-analysis to assess the relationship between the rate of CEs and LQTS individuals with confounding variables, including different gender, age, and QTc intervals. Moreover, a network meta-analysis was not only established to evaluate the effectiveness of different BBs, but also to provide the ranked efficacies of BBs treatment for preventing the recurrence of CEs in LQT1 and LQT2 patients. In conclusion, nadolol was recommended as a relatively effective strategy for LQT2 in order to improve the prognosis of patients during a long follow-up period. Frontiers Media S.A. 2020-12-14 /pmc/articles/PMC7768040/ /pubmed/33381033 http://dx.doi.org/10.3389/fphar.2020.579525 Text en Copyright © 2020 Han, Liu, Li, Qing, Zhai, Xia and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Review Han, Lu Liu, Fuxiang Li, Qing Qing, Tao Zhai, Zhenyu Xia, Zirong Li, Juxiang The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis |
title | The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis |
title_full | The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis |
title_fullStr | The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis |
title_full_unstemmed | The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis |
title_short | The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis |
title_sort | efficacy of beta-blockers in patients with long qt syndrome 1–3 according to individuals’ gender, age, and qtc intervals: a network meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768040/ https://www.ncbi.nlm.nih.gov/pubmed/33381033 http://dx.doi.org/10.3389/fphar.2020.579525 |
work_keys_str_mv | AT hanlu theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT liufuxiang theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT liqing theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT qingtao theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT zhaizhenyu theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT xiazirong theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT lijuxiang theefficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT hanlu efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT liufuxiang efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT liqing efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT qingtao efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT zhaizhenyu efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT xiazirong efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis AT lijuxiang efficacyofbetablockersinpatientswithlongqtsyndrome13accordingtoindividualsgenderageandqtcintervalsanetworkmetaanalysis |